| 2006 | A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma | 성주명 | Article |
| 2019 | A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study | 문영철 | Article |
| 2017 | A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalanprednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma | 문영철 | Article |
| 2014 | Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: A prospective multicenter study | 문영철 | Article |
| 2014 | Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: Web-based multicenter registry study | 문영철 | Article |
| 2014 | Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea | 문영철 | Article |
| 2009 | Clinical features and survival outcomes in patients with multiple myeloma: Analysis of web-based data from the korean myeloma registry | 문영철 | Article |
| 2021 | Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone | 문영철 | Article |
| 2017 | Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy | 문영철 | Article |
| 2013 | Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation | 문영철 | Article |
| 2018 | Escape from thymic deletion and anti-leukemic effects of T cells specific for hematopoietic cell-restricted antigen | 장준; 김주영 | Article |
| 2011 | Immunoglobulin D multiple myeloma: Response to therapy, survival, and prognostic factors in 75 patients | 문영철 | Article |
| 2021 | Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma | 문영철 | Article |
| 2012 | In vivo imaging of differences in early donor cell proliferation in Graft-versus-host disease hosts with different pre-conditioning doses | 장준 | Article |
| 2014 | Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients | 문영철 | Article |
| 2013 | Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT | 문영철 | Article |
| 2022 | Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909) | 문영철 | Article |
| 2018 | Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150) | 문영철 | Article |
| 2022 | Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma | 문영철 | Article |
| 2017 | The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: A retrospective multicenter study (KMM160) | 문영철 | Article |
